Cytidine
In clinical developmentAlso known as 1-beta-D-Ribofuranosylcytosine, Citidina, Cytosine riboside, Zytidin+1 more
1-beta-D-Ribofuranosylcytosine, Citidina, Cytosine riboside, Zytidin, Cytidin.
Recent clinical, regulatory, research and industry developments relating to this drug.
NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- Circulation research1
- Nucleic acids research1
- Chen L1
- Kong C1
- Kong X1
- Kozaeva E1
- Li P1
- Nielsen ZS1
- Nieto-Domínguez M1
- Nikel PI1
- Cardiovascular Research Center1
- Changzhou Medical Center of the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University and Department of Cardiology of the First Affiliated Hospital of Nanjing Medical University1
- Nanjing Drum Tower Hospital1
- The First Affiliated Hospital of Nanjing Medical University1
- The Novo Nordisk Foundation Center for Biosustainability1
- Yangpu Hospital1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials